According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
The product will be launched by NATCO's commercial partner Viatris.
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
It is used for the treatment of advanced colorectal and gastric cancer
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
According to industry sales data, the 10mg strength of Afinitor generated annual sales of US $ 392 million during the twelve months ending July 2021
Subscribe To Our Newsletter & Stay Updated
